The present invention aims to provided a novel production method of an enzalutamide crystal form in which wet crystals of enzalutamide are obtained in a step of crystallizing in the production process of the enzalutamide crystal form, and then 2-propanol which is solvated with enzalutamide and the B-type crystals are reduced. The present invention relates to a production method of an enzalutamide crystal form, which comprises a step of crystallizing for obtaining wet crystals of enzalutamide, and a step of drying the wet crystals, and comprises a step of washing using a mixed solvent of a good solvent and a poor solvent after the step of crystallizing.

Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N-oxides, and salts thereof, ##STR00001##
wherein Q.sup.1, Q.sup.2, X, R.sup.1, R.sup.1a and R.sup.2 are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling plant disease caused by a fungal pathogen comprising applying an effective amount of a compound or a composition of the invention.

Liquid-crystalline media are disclosed containing one or more compounds of formula I

##STR00001##

along with components containing these media for high-frequency technology, in particular phase shifters and microwave array antennas.

Shown is a bimesogenic compound having high solubility in a liquid crystal compound, a liquid crystal composition, a chiral dopant, an additive including an antioxidant or an ultraviolet light absorber, and a polymerizable liquid crystal compound, each of which is used in other bimesogenic compounds or a liquid crystal display device, while maintaining desired physical properties.

A compound is represented by formula (1), a liquid crystal composition contains the compound, conjugate fibers with an encapsulated liquid crystal obtained from the liquid crystal composition, and a liquid crystal display device is obtained from the conjugate fibers with the encapsulated liquid crystal.

MG.sup.1-Z.sup.a-Sp-Z.sup.b-MG.sup.2(1)

This disclosure relates to compounds containing both an NO-releasing moiety and an H.sub.2S-releasing moiety and the use of such compounds in treating inflammatory diseases, including cancers.

This disclosure relates to compounds containing both an NO-releasing moiety and an H.sub.2S-releasing moiety and the use of such compounds in treating inflammatory diseases, including cancers.

The present invention relates to a process for labeling compounds comprising thiol moieties with 3-arylpropiolonitrile compounds, to 3-arylpropiolonitrile compounds substituted with tag moieties and to specific 3-arylpropiolonitrile linkers.

The present invention relates to a process for labeling compounds comprising thiol moieties with 3-arylpropiolonitrile compounds, to 3-arylpropiolonitrile compounds substituted with tag moieties and to specific 3-arylpropiolonitrile linkers.

Disclosed are small molecule inhibitors of deubiquitinating enzymes (DUBs), and methods of using them. Certain compounds are selective for particular ubiquitin-specific proteases (USPs).

Disclosed are small molecule inhibitors of deubiquitinating enzymes (DUBs), and methods of using them. Certain compounds are selective for particular ubiquitin-specific proteases (USPs).